The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch
RaySearch Laboratories AB (publ) is proud to announce that The Royal Marsden NHS Foundation Trust, a specialist cancer center in the UK, will be the first in the world to implement online adaptive radiation therapy (OART) with RaySearch’s treatment planning system RayStation®* and oncology information system RayCare®* – including the new ARTemis* OART solution under development – in combination with the Radixact® Treatment Delivery System from Accuray.
The Royal Marsden is at the forefront of radiotherapy research in the UK and globally and has been using RayStation for conventional treatment planning since 2016. Thanks to funding from The Royal Marsden Cancer Charity, the center recently acquired two additional Radixact treatment delivery machines from Accuray with the intention to utilize these machines for OART.
OART uses the daily acquired patient images to optimize the treatment plan by taking into account the changes in the patient’s anatomy while the patient is still on the treatment couch. This procedure, which potentially can have significant benefits for the treatment of the patient, puts high demand on the acquired images by the delivery machine and an efficient information flow between the treatment planning system, the oncology information system and the treatment control system.
ARTemis is a collaborative effort between RaySearch and Accuray, aiming to provide an online adaptive solution for clinicians using the RayStation treatment planning system with the Radixact Treatment Delivery System. It will leverage RayStation’s capability for automated adaptive replanning, RayCare’s powerful clinical workflow management tools, and the Accuray ClearRTTM imaging, to facilitate an optimized solution for online adaptive therapy.
The Royal Marsden in Sutton plans to implement the full ARTemis package, which has also been funded by The Royal Marsden Cancer Charity. ARTemis is currently under development and The Royal Marsden aims to be the first center in the world to regularly perform OART on patients treated on the Radixact System.
Professor Uwe Oelfke, Head of the Joint Department of Physics of The Royal Marsden and The Institute of Cancer Research, London, says: “We are proud that The Royal Marsden will be the first in the world to provide this unique technology thanks to funding from The Royal Marsden Cancer Charity. The ARTemis platform will enable us to tailor treatment in real time for patients being treated on our two new Radixact machines, which are due to be installed in 2024 and 2025, allowing us to target their disease more precisely and reduce damage to healthy tissue. We look forward to developing this exciting new service with valued support from RaySearch and Accuray."
Johan Löf, founder and CEO, RaySearch, says: “I am a strong believer of the clinical benefits of adaptive radiation therapy. The tools have been available in RayStation for many years and RayCare has from the beginning been developed to facilitate the implementation of OART in clinical routine. In ARTemis we will have a very strong solution to enable online adaptive and I could not have asked for a better partner than The Royal Marsden, with which we have an established and fruitful collaboration, to be the pioneering center for this exciting new solution.”
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
About The Royal Marsden NHS Foundation Trust
The Royal Marsden opened its doors in 1851 as the world’s first hospital dedicated to cancer diagnosis, treatment, research and education. Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe seeing and treating over 59,000 NHS and private patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.
The Royal Marsden, with the ICR, is the only National Institute for Health and Care Research Biomedical Research Centre for Cancer. This supports pioneering research work carried out over a number of different cancer themes. The Royal Marsden Cancer Charity raises money solely to support The Royal Marsden, a world-leading cancer centre. It ensures Royal Marsden nurses, doctors and research teams can provide the very best care and develop life-saving treatments, which are used across the UK and around the world. From funding state-of-the-art equipment and ground-breaking research, to creating the very best patient environments, The Royal Marsden Cancer Charity will never stop looking for ways to improve the lives of people affected by cancer. royalmarsden.nhs.uk.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software has been told to over 1,000 centers in 43 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.
About RayCare
The RayCare®* oncology information system (OIS) is designed to support the many complex logistical challenges faced by today’s oncology clinics. RayCare is closely integrated with RayStation®* and provides seamless access to all the powerful planning tools in RayStation and RayCommand®. The system efficiently coordinates activities in radiation therapy and offers advanced features for clinical workflow automation, and adaptive radiation therapy. RayCare responds to the demand from clinics for a more user-friendly and workflow-oriented information system that can support the cancer care of the future.
* Subject to regulatory clearance in some markets.
Tags:
